Kentucky, Alaska and Alabama are the three states where weight loss drugs ... U.S. Food and Drug Administration (FDA) approved the semaglutide-based drug Wegovy for obesity. Before Wegovy, 190,000 people in the U.S. were claiming GLP-1 drugs each month ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications,

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their body weight fall by 5% or more after 28 days, with the number rising to 57% in the seven patients who received the 40-mg doses.

Expanding Medicaid coverage of these drugs could increase access for the almost 40% of adults and 26% of children with obesity in Medicaid,” wrote the research team led by se

Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive policies add to equity concerns around the blockbuster drugs,